How big is Xenon Pharmaceuticals, Inc.?

As of Jun 18, Xenon Pharmaceuticals, Inc. has a market capitalization of $2.43 billion, with net sales of $7.50 million and a net profit of -$251.45 million over the last four quarters. The company's shareholder's funds are $754.90 million, and total assets amount to $1.07 billion.

Market Cap: As of Jun 18, Xenon Pharmaceuticals, Inc. has a market capitalization of 2,432.46 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Xenon Pharmaceuticals reported net sales of 7.50 million and a net profit of -251.45 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 754.90 million, while total assets were reported at 1,067.09 million.

What does Xenon Pharmaceuticals, Inc. do?

Xenon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Canada, focused on developing therapeutics for orphan diseases. As of March 2025, it reported net sales of $8 million and a net loss of $65 million, with a market cap of approximately $2.43 billion.

Overview: <BR>Xenon Pharmaceuticals, Inc. is a Canada-based clinical-stage biopharmaceutical company engaged in discovering and developing differentiated therapeutics for orphan indications within the Pharmaceuticals & Biotechnology industry, categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -65 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,432.46 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.78 <BR>Return on Equity: -35.72% <BR>Price to Book: 3.46<BR><BR>Contact Details: <BR>Address: 3650 Gilmore Way, BURNABY BC: V5G 4W8 <BR>Tel: 1 604 4843300 <BR>Website: http://www.xenon-pharma.com/

Should I buy, sell or hold Xenon Pharmaceuticals, Inc.?

Who are in the management team of Xenon Pharmaceuticals, Inc.?

As of March 2022, the management team of Xenon Pharmaceuticals, Inc. includes Mr. Michael Tarnow (Independent Chairman), Dr. Simon Pimstone (Executive Chairman), Mr. Patrick Machado, Dr. Mohammad Azab, Dr. Clarissa Desjardins, and Mr. Steven Gannon (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Xenon Pharmaceuticals, Inc. includes the following members:<BR><BR>- Mr. Michael Tarnow, Independent Chairman of the Board<BR>- Dr. Simon Pimstone, Executive Chairman of the Board<BR>- Mr. Patrick Machado, Director<BR>- Dr. Mohammad Azab, Independent Director<BR>- Dr. Clarissa Desjardins, Independent Director<BR>- Mr. Steven Gannon, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is Xenon Pharmaceuticals, Inc. overvalued or undervalued?

As of May 12, 2025, Xenon Pharmaceuticals is considered a risky investment due to its high Price to Book Value of 3.45, negative EV to EBITDA of -6.47, and poor ROE of -35.72%, alongside underperforming the S&P 500 with a return of -5.81% compared to the index's 17.14%.

As of 12 May 2025, the valuation grade for Xenon Pharmaceuticals, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its high Price to Book Value of 3.45 and negative EV to EBITDA of -6.47, alongside a troubling ROE of -35.72%. Comparatively, Madrigal Pharmaceuticals, Inc. also carries a risky valuation with a P/E of -35.88, while Cytokinetics, Inc. shares a similar risky status with a P/E of -10.74.<BR><BR>In terms of stock performance, Xenon Pharmaceuticals has underperformed relative to the S&P 500 over the past year, with a return of -5.81% compared to the index's 17.14%. This trend reinforces the notion that the stock may not be a favorable investment at its current valuation levels.

Is Xenon Pharmaceuticals, Inc. technically bullish or bearish?

As of September 9, 2025, Xenon Pharmaceuticals, Inc. shows a neutral technical stance with mixed indicators, transitioning from mildly bearish to sideways, while underperforming against the S&P 500 in the short term but significantly outperforming over the past five years.

As of 9 September 2025, the technical trend for Xenon Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators across different time frames. The weekly MACD and Bollinger Bands are bullish, while the monthly MACD and Bollinger Bands are bearish. The daily moving averages indicate a mildly bearish trend. The KST shows bullish momentum weekly but bearish monthly, and the Dow Theory presents a mildly bearish weekly outlook alongside a mildly bullish monthly perspective. <BR><BR>In terms of performance, the stock has underperformed against the S&P 500 over the past month, year-to-date, and year, but has significantly outperformed over the last five years.